1Schuhze JL. A pilot study of combined immamothempy with autologous adoptive tumour - specific T- cell transfer, vaccination with CD40 - activated malignant B cells and intedeukin 2.Br J Haematol,2001,113(2) :455 - 460.
2Margolin K, Forman SJ. Immunothcrapy with interleukin- 2 after hematopoietic cell transplantation for hematologic maligmncy. Cancer J Sci Am,2000,6(Suppl 1):s33- 38.
3Bruserod O, Wendelbee O. Division of Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Norway. oystein.bruserud@haukeland.no .Biological treatment in acute myelogenous leukaemia: how should T - cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther, 2001,1(6) : 1 005 - 1 016.
4Czuczman M, Grillo- Lopez AT, White CA, et al. RITUXANTM/CHOP chemo immunotherapyl : Int J Hematol,2003,77(2): 175- 179.
5Colombo BM, Lacave R, Pioche - Durieu C, et al. Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia. Immunology,2000,99( 1 ) :8 - 15.
6Weigel BJ, Nath N, Taylor PA,et al. Comparative analysis of murine marrow- derived dendritic cells generated by Flt3L or GM - GSF/IL - 4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood,2002,100(12) :4 169 - 4 176.
7Link C.J, Seregina T, Traynor A, et al. Cellular suicide therapy of malignant disease. Oncologist, 2000,5 ( 1 ) : 68 - 74.
